Delivering cancer drugs where they belong.
TargetingCT is a pre-seed company developing a new class of actively targeted liposomal nanomedicines, designed to deliver potent cancer drugs directly to tumor cells with greater precision and fewer side effects than current therapies.
Our Mission
Accelerating safer, more effective treatments for solid tumors.
We aim to accelerate the development of safer, more effective treatments for solid tumors by building on established drug-delivery platforms and advancing them with precise, clinically translatable targeting technology. By combining proven liposomal science with active targeting, we can concentrate powerful therapies at the tumor while sparing healthy tissue.
Our Approach
Precision built on established platforms.
Three principles guide how we design nanomedicines that hit the target and protect the patient.
Active targeting
Surface ligands guide our nanoparticles to tumor cells, improving precision and reducing off-target exposure.
Liposomal delivery
A well-established lipid nanoparticle platform carries potent payloads safely through the bloodstream to the tumor.
Clinical translatability
We advance proven science with targeting technology engineered to move efficiently from bench to bedside.
Contact us
Address
Machal 58Tel Aviv, Israel